The FDA granted accelerated approval to tafasitamab-cxix (Monjuvi, MorphoSys US/Incyte) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem cell transplantation.
The approval was based on data from the ongoing multicenter, phase 2, single-arm, open-label L-MIND trial (ClinicalTrials.gov Identifier: NCT02399085), in which investigators are evaluating